What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1.
What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1.
复制标题
DOI：
10.1101/cshperspect.a029389
复制
发表时间：
2018-05
影响因子：
7.2
通讯作者：
G. Victora;H. Mouquet
中科院分区：
文献类型：
--
作者：
G. Victora;H. Mouquet
大多数针对HIV-1的广泛中和抗体共同具有极端程度的体细胞超突变（SHM），这与它们中和多种病毒株的能力相关。然而，通过免疫实现这种极端的SHM仍然是一个挑战。在这里，我们讨论了如何在HIV-1感染的抗原变异可能会加剧SHM，允许多个迭代周期的亲和力成熟的生发中心，并推测如何通过疫苗接种重演。
Most broadly neutralizing antibodies to HIV-1 have in common an extreme degree of somatic hypermutation (SHM), which correlates with their ability to neutralize multiple viral strains. However, achieving such extreme SHM by immunization remains a challenge. Here, we discuss how antigenic variation during HIV-1 infection may work to exacerbate SHM by permitting multiple iterative cycles of affinity maturation in germinal centers, and speculate on how this could be recapitulated through vaccination.